Tavapadon, an oral dopamine receptor agonist, showed promising results in two phase 3 trials for Parkinson’s disease (PD). In the TEMPO-3 trial, patients with PD and motor fluctuations receiving tavapadon in addition to levodopa had significantly increased “on” time without dyskinesias compared to placebo. Tavapadon was well tolerated, with modest decreases in blood pressure and weight observed. Other common side effects included nausea and dizziness. The results suggest that tavapadon is a potentially effective treatment for PD, with a unique dopamine receptor profile that may reduce impulse control behavior disorders. Additional TEMPO trials are ongoing to further evaluate the drug’s efficacy and safety.
Source link
Tavapadon Marches on in Parkinson’s Disease
